LRP2 (rs2302694) mutations were detected in a range of cancers, with melanoma (28.18%), uterine sarcoma (17.99%), and lung squamous cell carcinoma (16.32%) with the highest mutation rates (24). Here, LRP2 is linked to melanoma.